US 12275955
Combining iPSC derived effector cell types for immunotherapy use
granted A61KA61K2239/30A61K2239/31
Quick answer
US patent 12275955 (Combining iPSC derived effector cell types for immunotherapy use) held by Fate Therapeutics, Inc. expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Fate Therapeutics, Inc.
- Grant date
- Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 40
- CPC classes
- A61K, A61K2239/30, A61K2239/31, A61K2239/38, A61K2239/48